FibroGen to implement 1-for-25 reverse stock split; shares down 15%

Stock Information for FibroGen Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FibroGen Inc

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes
FibroGen to Report Second Quarter 2025 Financial Results
FibroGen Announces 1-for-25 Reverse Stock Split
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
FibroGen to Report First Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.